Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
Sales | 220 | 1,350 | 3,355 | 473 | 1,496 |
Cost of Goods | 423 | 908 | 83 | 77 | 79 |
Gross Profit | -203 | 442 | 3,272 | 396 | 1,417 |
Operating Expenses | 18,182 | 17,813 | 20,484 | 31,053 | 17,834 |
Operating Income | -17,962 | -16,463 | -17,129 | -30,580 | -16,338 |
Interest Expense | 1,167 | 985 | 239 | 0 | 0 |
Other Income | -17 | -15 | -5 | 17 | 11 |
Pre-tax Income | -19,146 | -17,463 | -17,373 | -30,563 | -16,327 |
Income Tax | -16 | 8 | -199 | 11 | -185 |
Net Income Continuous | -19,130 | -17,471 | -17,174 | -30,574 | -16,142 |
Net Income Discontinuous | -66 | 76 | 69 | -106 | 499 |
Net Income | $-19,196 | $-17,395 | $-17,105 | $-30,680 | $-15,643 |
EPS Basic Total Ops | -456.78 | -495.24 | -502.38 | -914.65 | -457.33 |
EPS Basic Continuous Ops | -452.02 | -497.62 | -504.76 | -914.65 | -485.91 |
EPS Basic Discontinuous Ops | -5.53 | 2.38 | 2.38 | 0.00 | 28.58 |
EPS Diluted Total Ops | -456.78 | -495.24 | -502.38 | -914.65 | -6,459.73 |
EPS Diluted Continuous Ops | -452.02 | -497.62 | -504.76 | -914.65 | -6,459.73 |
EPS Diluted Discontinuous Ops | -5.53 | 2.38 | 2.38 | 0.00 | 0.00 |
EBITDA(a) | $-17,318 | $-15,667 | $-16,569 | $-30,129 | $-15,800 |